Takeda’s drug for acute hereditary angioedema seizure to get larger benefits

24 February 2021 - Takeda Pharmaceutical Korea said that the Ministry of Health and Welfare would grant expanded reimbursement for ...

Read more →

Anti-cancer drugs Ninlaro, Lutathera to get insurance benefits from March

24 February 2021 - Takeda’s multiple myeloma treatment Ninlaro (ixazomib) and Novartis’ neuroendocrine tumour drug Lutathera (lutetium oxodotreotide) will get ...

Read more →

Parkinson’s disease drug Equifina gets insurance benefits

1 February 2021 - The government has decided to grant health insurance benefits to Eisai’s Parkinson’s disease treatment, Equifina (safinamide), ...

Read more →

Regulators OK Yuhan's Leclaza as 31st novel drug

18 January 2020 - Yuhan said Monday that it has received sales approval for Leclaza (lazertinib), a drug targeting epidermal ...

Read more →

Janssen's ulcerative colitis treatment to receive reimbursement

12 January 2021 - Janssen Pharmaceutical said Tuesday that the Ministry of Health and Welfare would begin to reimburse Stelara, ...

Read more →

Tiered drug pricing policy widens price difference among generic drugs

30 December 2020 - In July, the nation implemented a “tiered system” to restructure the drug-pricing method, which called for ...

Read more →

Will HIRA resume talk to grant benefits for anti-diabetic combo drugs?

22 October 2020 - Three makers of SGLT-2 inhibiting anti-diabetic drugs said they would seek changes in approval conditions to ...

Read more →

Daewoong's antipyretic unable to get insurance benefits

13 October 2020 - Daewoong Pharmaceutical has failed to list Fiblast (trafermin), a burn treatment drug developed by Japan's Kaken ...

Read more →

Will Tagrisso win insurance benefits in Korea, too?

14 September 2020 - AstraZeneca’s Tagrisso, targeted therapy for lung cancer, has won recognition as the first-line standard treatment for ...

Read more →

‘Korea should introduce indication-specific drug pricing’

31 August 2020 - “Korea must introduce a system to apply different prices for a drug’s multiple indications, to guarantee ...

Read more →

Drug makers to sue government for limiting choline alfoscerate benefit

27 August 2020 - Manufacturers of choline alfoscerate, a dementia drug, are reportedly preparing to file an administrative lawsuit against ...

Read more →

Takeda expects more effective IBD treatment with Kynteles' expanded reimbursement

12 August 2020 - Takeda Korea is strengthening its position in the domestic inflammatory bowel disease market with Kynteles receiving ...

Read more →

Petitioner demands insurance benefit for breast cancer drug Kadcyla

11 August 2020 - A woman has requested that the government grant reimbursement for using Kadcyla of Roche in treating ...

Read more →

Rheumatoid arthritis drug Rinvoq gets insurance benefit

7 August 2020 - AbbVie Korea’s rheumatoid arthritis treatment Rinvoq (upadacitinib) has obtained the national health insurance benefit. ...

Read more →

ISPOR announces Virtual ISPOR Asia Pacific 2020

3 August 2020 - ISPOR—The Professional Society for Health Economics and Outcomes Research announced its Virtual ISPOR Asia Pacific 2020 ...

Read more →